Submit Deal

GALAPAGOS NV

Summary

Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. The company is based in Mechelen, Belgium.

Deals Overview

Total Deals4

Valued Deals4

Total Value£ 1.09 B

Avg. Deal Size£ 272 M

Market Context

Subsidiaries

FIDELTA

1 transaction

Senior Management

Onno van de Stolpe
CEO
Onno van de Stolpe
CEO
Paul Stoffels
CEO and Chairman

Senior Management

Onno van de Stolpe
CEO
Onno van de Stolpe
CEO
Paul Stoffels
CEO and Chairman

Sort

14 Jul 2019|Belgium|Biotechnology

Target: GALAPAGOS NV

Bidder: GILEAD SCIENCES

15 Service Providers

7 Target | 8 Bidder

36 Dealmakers

24 Target | 12 Bidder

£ 849 M

Value

23 Nov 2020|Croatia|Biotechnology

Target: FIDELTA

Bidder: SELVITA SA

4 Service Providers

1 Target | 1 Bidder | 2 Vendor

12 Dealmakers

1 Target | 2 Bidder | 9 Vendor

£ 28 M

Value

30 Oct 2023|Belgium|Medical Supplies

Target: GALAPAGOS (JYSELECA BUSINESS)

Bidder: ALFASIGMA SPA

14 Service Providers

9 Bidder | 5 Vendor

23 Dealmakers

10 Bidder | 13 Vendor

£ 148 M

Value

22 Feb 2024|United States|Pharmaceuticals

Target: FRONTIER MEDICINES

Bidder: GALAPAGOS NV

4 Service Providers

2 Target | 2 Bidder

4 Dealmakers

2 Target | 2 Bidder

£ 63 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy